View Latest Medical and Pharma Bids and Tenders

Pharmaceutical Discount Agreements From February 1, 2025 For Various Active Ingredients Within The Framework Of An Open-House Procedure

Conclusion Of Non-Exclusive Discount Agreements Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredients Mentioned With The Possibility Of Conclusion Within The Framework Of The So-Called Open House Procedure.

Conclusion Of Non-Exclusive Discount Agreements Pursuant To Section 130A Paragraph 8/130C Paragraph 1 Sgb V For Medicinal Products Containing The Active Ingredient Iron(Iii) Sodium Gluconate Complex (B03Ac07) Within The Framework Of A So-Called Open-House Model.

Conclusion Of Non-Exclusive Discount Agreements Pursuant To Section 130A Paragraph 8/130C Paragraph 1 Sgb V For Medicinal Products Containing The Active Ingredient Iron(Iii) Sodium Gluconate Complex (B03Ac07) Within The Framework Of A So-Called Open-House Model.

Pharmaceutical Discount Agreements From 01.12.2024 For Various Active Ingredients As Part Of An Open-House Procedure

Conclusion Of Non-Exclusive Discount Agreements Pursuant To Section 130 A Paragraph 8 Sgb V With The Active Ingredient Iron (Ii) Ion Ret

Open House Contracts For Multiple Active Ingredients/Active Ingredient Combinations

Conclusion Of Non-Exclusive Discount Agreements In Accordance With Sections 130A Paragraph 8/130C Paragraph 1 Sgb V For Medicines With The Active Ingredient Iron (Ii) Sulfate (B03Aa07) As Part Of A So-Called Open House Model.

Conclusion Of Non-Exclusive Discount Agreements In Accordance With Sections 130A Paragraph 8/130C Paragraph 1 Sgb V For Medicines With The Active Ingredient Iron (Ii) Sulfate (B03Aa07) As Part Of A So-Called Open House Model.

Conclusion Not Excluding Drug Discount Agreement. According To Section 130A Paragraph 8 Sgb V By Means Of An Open House Model For The Active Ingredient Iron Carboxymaltose (Atc Code According To Who: B03Ac; Official Atc: B03Ac01)